Gilead Hit With $200M Verdict In Merck Drug Patent Row
A California federal jury found on Thursday that Gilead Sciences must pay $200 million to rival Merck for infringing two patents covering a key ingredient used in Gilead's blockbuster hepatitis C...To view the full article, register now.
Already a subscriber? Click here to view full article